Trial Search: "LIVER"



Treatment trials which apply specifically to your search:


0C-14-2

Trial Leaders:
David Quinn

AN OPEN-LABEL, PHASE 2 BASKET STUDY OF NERATINIB IN PATIENTS WITH SOLID TUMORS WITH SOMATIC ACTIVATING HER MUTATIONS

Treatment:
Chemotherapy: Systemic

0C-14-9

Trial Leaders:
Anthony El-Khoueiry

A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of ceralasertib in combination with Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients with Advanced Solid Malignancies

Treatment:
Chemotherapy: Systemic

0C-15-2

Trial Leaders:
Jorge Nieva

GO40782 / An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Treatment:
Chemotherapy: Systemic

0C-16-6

Trial Leaders:
Anthony El-Khoueiry

PhI-87 Phase I Clinical Trial of M6220 (VX-970) in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-16-8

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects with Advanced Refractory Cancers

Treatment:
Chemotherapy: Local

0C-17-1

Trial Leaders:
Anthony El-Khoueiry

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 skip mutations and c-Met Dysregulation Advance Solid Tumors

Treatment:
Other

0C-17-11

Trial Leaders:
Diana Hanna

Phase 1 trial of ZW25 in patients with locally advanced (unresectable) and/or metastatic HER2-expressing cancers

Treatment:
Other

0C-17-17

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2 First-in-human Study of BMS-986258 Alone and in Combination with Nivolumab in Advanced Malignant Tumors

Treatment:
Immunotherapy

0C-17-2

Trial Leaders:
David Quinn

A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects with Advanced Cancers

Treatment:
Biological Response Modifier
Chemotherapy: Systemic

0C-18-12

Trial Leaders:
Anthony El-Khoueiry

A phase I, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK3368715 in participants with solid tumors and DLBCL

Treatment:
Chemotherapy: Systemic

0C-18-16

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2 Open-label, Multicenter Study To Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884)in Subjects With Advanced or Refractory Cancer and in Subjects who have Progressed During Treatment with a PD-1/PD-L1 Inhibitor as their Most Recent Therapy

Treatment:
Immunotherapy

0C-18-2

Trial Leaders:
Anthony El-Khoueiry

A Phase I Study of FID-007 in Patients with Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-18-20

Trial Leaders:
Jacob Thomas

A Phase 1 Dose-escalation Study of FF-10832 Monotherapy or in Combination with Nab-paclitaxel for the Treatment of Advanced Solid Tumors

Treatment:
(No treatments specified)

0C-18-21

Trial Leaders:
Diana Hanna

A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.

Treatment:
Chemotherapy: Systemic
Immunotherapy

0C-18-23

Trial Leaders:
Anthony El-Khoueiry

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms

Treatment:
Immunomodulator

0C-18-24

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176

Treatment:
Immunotherapy

0C-18-5

Trial Leaders:
Heinz Josef Lenz

An open-label, Phase I trial to determine the maximum-tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 905677 administered intravenously in patients with advanced solid tumours

Treatment:
Chemotherapy: Systemic

0C-18-6

Trial Leaders:
Heinz Josef Lenz

PhII-168: A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors

Treatment:
Chemotherapy: Local

0C-18-7

Trial Leaders:
Anthony El-Khoueiry

A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas

Treatment:
Chemotherapy: Systemic

0C-18-8

Trial Leaders:
Jorge Nieva

A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144/LN-145/LN-145-S1) in Patients with Solid Tumors

Treatment:
Autologous Bone Marrow Transplant
Immunotherapy

0C-19-10

Trial Leaders:
Anthony El-Khoueiry

A Phase 1, Open-label, Dose-escalation and Expansion Study of MEDI1191 Administered Intratumorally as Monotherapy and in Combination with Durvalumab in Subjects with Advanced Solid Tumors

Treatment:
Immunotherapy

0C-19-12

Trial Leaders:
Heinz Josef Lenz

A Phase 1a/b Dose-Finding Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

Treatment:
Chemotherapy: Systemic
Other

0C-19-13

Trial Leaders:
Anthony El-Khoueiry

QUILT-3.055: A Phase 2b, Single-Arm, Multicohort, Open-Label Study of ALT-803 in Combination with a PD-1/PD-L1 Checkpoint Inhibitor in Patients Who Have Disease Progression Following an Initial Response to Treatment with PD-1/PD-L1 Checkpoint Inhibitor Therapy

Treatment:
Immunotherapy

0C-19-15

Trial Leaders:
Anthony El-Khoueiry

A Phase 1 Study of AGEN1223, a Bispecific Fc-Engineered Anti-GITR-OX40 Antibody in Subjects with Advanced Solid Tumors

Treatment:
Immunotherapy

0C-19-2

Trial Leaders:
Jacob Thomas

A Phase 1, open label, first-in-human study of TR1801-ADC, an antibody drug conjugate (ADC), in patients with select solid tumors expressing c-Met

Treatment:
Other

0C-19-20

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AFM24 in Patients with Advanced Solid Cancers

Treatment:
Immunotherapy

0C-19-21

Trial Leaders:
Diana Hanna

A Phase I Study of GNX102 in patients with Advanced Solid Tumors

Treatment:
Immunotherapy

0C-19-22

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients with Advanced Cancers Associated with Mesothelin Expression Who Have Failed Standard Available Therapy

Treatment:
Biological Response Modifier

0C-19-3

Trial Leaders:
Jacob Thomas

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

Treatment:
Immunotherapy

0C-19-4

Trial Leaders:
Anthony El-Khoueiry

Phase 1 Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety of Lorlatinib in Advanced Cancer Patients

Treatment:
Immunotherapy

0C-19-6

Trial Leaders:
Anthony El-Khoueiry

A Phase I Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor (CDAi) with Oral Decitabine in Subjects with Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-19-7

Trial Leaders:
Anthony El-Khoueiry

A Phase 1 Study of AGEN1181, an Fc-Engineered Anti–CTLA-4 Monoclonal Antibody as Monotherapy and in Combination with AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancer

Treatment:
Immunotherapy

0C-19-8

Trial Leaders:
Heinz Josef Lenz

A multicentre, open-label, non randomised first in human study of NG-641, an oncolytic transgene expressing adenoviral vector, in patients with metastatic or advanced epithelial tumours (STAR)

Treatment:
Immunomodulator

0C-20-1

Trial Leaders:
Anthony El-Khoueiry

A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability,Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications

Treatment:
Immunotherapy

0C-20-2

Trial Leaders:
Anthony El-Khoueiry

Phase 1/1b Study to Evaluate the Safety and Activity of TTX-030 (Anti-CD39) in Combination with Budigalimab and/or Chemotherapy in Subjects with Advanced Solid Tumors

Treatment:
(No treatments specified)

0C-20-6

Trial Leaders:
Anthony El-Khoueiry

Phase 2 Trial of Voyager V1 (Vesicular Stomatitis Virus Expressing NIS and Human Interferon Beta, VV1), in Combination with Cemiplimab in patients with Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Melanoma or Endometrial Carcinoma

Treatment:
Immunotherapy

0C-20-7

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/1b, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1454 alone and in Combination with Ipilimumab and Nivolumab

Treatment:
Other

0C-20-8

Trial Leaders:
Heinz Josef Lenz

First-In-Human Dose-Escalation Study of STP1002 in Patients with Advanced-Stage Solid Tumors

Treatment:
Other

0C-20-9

Trial Leaders:
Anthony El-Khoueiry

A Phase 1 Study of AGEN2373, an Anti–CD137 Monoclonal Antibody, in Subjects with Advanced Cancer

Treatment:
Other

0S-08-9

Trial Leaders:
David Quinn

Short-Term Fasting Prior to Platinum-Based Chemotherapy: Feasibility and Impact on Toxicity

Treatment:
Chemotherapy: Systemic

0S-10-3

Trial Leaders:
David Quinn

A Randomized, Phase II Clinical Trial of a Controlled Diet Prior to Selected Chemotherapy Treatment in Breast and Prostate Cancer to Evaluate the Impact on Toxicity and Efficacy.

Treatment:
Other

0S-16-13

Trial Leaders:
David Quinn

A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

Treatment:
Chemotherapy: Systemic

0S-16-18

Trial Leaders:
Anthony El-Khoueiry

A Phase Ib Study of Guadecitabine (SGI-110) and Durvalumab (MEDI 4736) in Patients with Advanced Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, and Cholangiocarcinoma/Gallbladder Cancer

Treatment:
Chemotherapy: Systemic
Other

0S-16-8

Trial Leaders:
Jorge Nieva

A Phase IIa Trial of sEphB4-HSA in Combination with Anti PD-1 Antibody (Pembrolizumab, MK3475) in Patients with Non-Small Cell Lung and Head/Neck Cancer

Treatment:
Chemotherapy: Systemic

0S-17-8

Trial Leaders:
Gino In

PhII-159 A Phase II Study of Talimogene laherparepvec Followed by Talimogene laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors

Treatment:
Immunotherapy

0S-19-6

Trial Leaders:
Jorge Nieva

A Phase I/II Study of TheraT® Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients with HPV 16+ Confirmed Cancers

Treatment:
Immunotherapy
Vaccine

0S-20-1

Trial Leaders:
Gino In

Short-term Fasting Prior to Standard Checkpoint Blockade Using PD-1/PD-L1 Inhibition: a Pilot Safety and Feasibility Study

Treatment:
Other

0S-20-2

Trial Leaders:
Syma Iqbal

PhII-201: A Phase 2 Study of XL184 (Cabozantinib) in Combination with Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas

Treatment:
(No treatments specified)

10M-18-2

Trial Leaders:
Gino In

Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I only).

Treatment:
Chemotherapy: Systemic

10M-19-3

Trial Leaders:
Jacob Thomas

A Phase 1/2a Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab Administered in Combination with Ipilimumab or Ipilimumab Alone in Participants with Unresectable or Metastatic Melanoma Who Have Progressed on Anti-PD-1 Therapy

Treatment:
Immunotherapy

11S-17-1

Trial Leaders:
James Hu

PhII-148 A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma

Treatment:
Biological Response Modifier

13NHL-17-1

Trial Leaders:
Kevin Kelly

A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/ Refractory Indolent Non-Hodgkin Lymphoma (INHL)

Treatment:
Chemotherapy: Systemic
Other

13NHL-19-2

Trial Leaders:
Ann Mohrbacher

An Open label, Phase I/II study to evaluate the safety and efficacy of Tenalisib (RP6530), a novel PI3K d/? dual inhibitor given in combination with a histone deacetylase (HDAC) inhibitor, Romidepsin in adult patients with relapsed/refractory T-cell Lymphoma

Treatment:
Immunotherapy

14SK-19-1

Trial Leaders:
Gino In

Evaluating the PD-1 checkpoint inhibitor, Cemiplimab, as neoadjuvant therapy in high risk localized, locally recurrent, and regionally advanced cutaneous squamous cell carcinoma: a Phase II pilot study

Treatment:
Immunotherapy

14SK-19-2

Trial Leaders:
Jacob Thomas

Phase 1 Trial of Intralesional Immunotherapy with IFx-Hu2.0 Vaccine in Patients with Advanced Merkel Cell Carcinoma or Cutaneous Squamous Cell Carcinoma

Treatment:
Immunotherapy
Vaccine

18M-18-1

Trial Leaders:
Jorge Nieva

PhII-175: Phase 1 Safety Run-In and Phase 2 Randomized Clinical Trial of Anetumab Ravtansine and MK-3475 (Pembrolizumab) Compared to MK-3475 (Pembrolizumab) Alone for Mesothelin-Positive Malignant Pleural Mesothelioma

Treatment:
Immunotherapy

1B-10-3

Trial Leaders:
Julie Lang

Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2.

Treatment:
Chemotherapy: Systemic

1B-13-1

Trial Leaders:
Janice Lu

A Phase II Study of Neratinib Alone and in Combination with Fulvestrant in Metastatic HER2 Non-amplified but HER2 Mutant Breast Cancer

Treatment:
Chemotherapy: Systemic

1B-17-3

Trial Leaders:
Jason Ye

Prone Partial Breast Irradiation (PBI): Prospective Randomized Controlled Non-Inferiority Trial to Compare Radiation Fibrosis with Five versus Three Fractions

Treatment:
Radiation: External

2N-17-3

Trial Leaders:
Jorge Nieva

A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)

Treatment:
Chemotherapy: Systemic

2N-19-2

Trial Leaders:
Jason Ye

A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)

Treatment:
Immunotherapy
Radiation: External

2N-20-3

Trial Leaders:
Jorge Nieva

A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy Versus Placebo with Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)

Treatment:
Chemotherapy: Systemic

2O-19-1

Trial Leaders:
Jorge Nieva

PhII-192: Randomized Phase II Trial of Topotecan Plus M6620 (VX-970) Vs. Topotecan Alone in Patients with Relapsed Small-Cell Lung Cancer

Treatment:
Chemotherapy: Systemic
Other

3A-15-1

Trial Leaders:
Syma Iqbal

PHII-133: Part A: A Multi-Institutional Phase II Study of Nivolumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal. Part B: A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal

Treatment:
Immunotherapy

3BD-18-1

Trial Leaders:
Anthony El-Khoueiry

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: the PROOF Trial

Treatment:
Chemotherapy: Systemic
Other

3C-17-3

Trial Leaders:
Heinz Josef Lenz

A Phase I/II Study of Regorafenib and Pembrolizumab in Metastatic Colorectal Cancer Patients in 3rd and 4th line setting

Treatment:
Immunotherapy

3C-18-10

Trial Leaders:
Heinz Josef Lenz

A Randomized, Multicenter, Parallel-Group, Phase III Study To Compare The Efficacy Of Arfolitixorin Versus Leucovorin In Combination With 5-Fluorouracil, Oxaliplatin, And Bevacizumab In Patients With Advanced Colorectal Cancer

Treatment:
(No treatments specified)

3C-19-1

Trial Leaders:
Heinz Josef Lenz

A Phase 1b/2 Study of Onvansertib (PCM-075) in Combination with FOLFIRI and Bevacizumab for Second-Line Treatment of Metastatic Colorectal Cancer in Patients with a Kras Mutation

Treatment:
(No treatments specified)

3C-19-3

Trial Leaders:
Heinz Josef Lenz

PhII-186:A Phase 2 Study of Savolitinib in Subjects with MET Amplified Metastatic Colorectal Cancer

Treatment:
Other

3C-19-5

Trial Leaders:
Heinz Josef Lenz

Relapsed/Refractory Microsatellite-stable (MSS) Colorectal Cancer (CRC) Immunotherapy-naïve Subjects Treated with Tilsotolimod in Combination with Nivolumab and Ipilimumab (Cohort 3) Main Study:Study of Tilsotolimod in Combination with Nivolumab and Ipilimumab for the Treatment of Solid Tumors

Treatment:
Immunotherapy

3C-19-6

Trial Leaders:
Heinz Josef Lenz

An Open-Label, Multicenter, Non-Randomized, Dose-Confirmation and Cohort-Expansion Phase 1b Study to Evaluate the Safety,Tolerability, and Anti-Tumor Activity of ATP128, with or without BI 754091, in Patients with Stage IV Colorectal Cancer

Treatment:
Immunotherapy
Vaccine

3C-20-2

Trial Leaders:
Heinz Josef Lenz

PULSE: A Randomized, Phase II Open Label Study of PanitUmumab RechaLlenge Versus Standard Therapy after Progression on Anti-EGFR Therapy in Patients with Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

Treatment:
Immunotherapy

3C-20-3

Trial Leaders:
Heinz Josef Lenz

MOUNTAINEER: A Phase 2, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer

Treatment:
Immunotherapy

3C-20-5

Trial Leaders:
Heinz Josef Lenz

A Randomized Phase II Study of Regorafenib Followed by Anti-EGFR monoclonal antibody therapy Versus the Reverse Sequencing for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin and irinotecan (REVERCE II)

Treatment:
Chemotherapy: Local

3E-17-2

Trial Leaders:
Syma Iqbal

Multicenter, Randomized Phase II Study Evaluating Pembrolizumab in Combination with Chemotherapy and Chemoradiation in Locally Advanced Esophageal Adenocarcinoma

Treatment:
Chemotherapy: Systemic

3G-17-2

Trial Leaders:
Syma Iqbal

A Phase Ib/II, Open-Label, Multicenter, Randomized, Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Locally Advanced Unresectable Or Metastatic Gastric Or Gastroesophageal Junction Cancer Or Esophageal Cancer (Morpheus Gastric And Esophageal Cancer)

Treatment:
Biological Response Modifier
Chemotherapy: Systemic
Immunotherapy

3G-18-3

Trial Leaders:
Syma Iqbal

Phase 2 Study of ZW25 Plus First-line Combination Chemotherapy in HER2 Expressing Gastroesophageal Adenocarcinoma (GEA)

Treatment:
Immunotherapy

3G-19-1

Trial Leaders:
Syma Iqbal

A Phase II Study of Preoperative Pembrolizumab for Mismatch-Repair Deficient, Epstein-Barr Virus Positive and PD-L1 Positive Gastric Cancer followed by Chemotherapy and Chemoradiation with Pembrolizumab

Treatment:
Chemotherapy: Systemic

3G-19-2

Trial Leaders:
Syma Iqbal

A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOXCompared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Treatment:
Chemotherapy: Systemic

3G-19-3

Trial Leaders:
Syma Iqbal

A phase 2, open-label, single-arm trial of Trastuzumab deruxtecan (DS-8201A) in HER2 Positive, unresectable or metastatic Gastric or Gastro-Esophageal Junction (GEJ) adenocarcinoma subjects who have Progressed on or after a trastuzumabcontaining Regimen

Treatment:
Chemotherapy: Systemic

3G-20-1

Trial Leaders:
Syma Iqbal

A Phase 2/3 Trial to Evaluate Margetuximab in Combination with INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients with Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer

Treatment:
Chemotherapy: Systemic
Immunotherapy

3G-20-2

Trial Leaders:
Syma Iqbal

A Randomised Phase III Double-Blind Placebo-Controlled Study of regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)

Treatment:
Chemotherapy: Local

3GB-14-1

Trial Leaders:
Anthony El-Khoueiry

A phase II multicenter, single arm study of oral BGJ398 in adult patients with advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or other FGFR genetic alterations who failed or are intolerant to platinum-based chemotherapy

Treatment:
Chemotherapy: Systemic

3L-17-1

Trial Leaders:
Anthony El-Khoueiry

A Phase I Open Label, Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRS Specific for Alpha Fetoprotein (AFPC332T) in HLA-A2 Positive Subjects with Advanced Hepatocellular Carcinoma (HCC) or any other AFP expressing tumor types

Treatment:
Other

3L-17-5

Trial Leaders:
Anthony El-Khoueiry

A multicenter, non-randomized, open-label dose escalation Phase Ib study of regorafenib in combination with pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) with no prior systemic therapy.

Treatment:
Anti-Angiogenesis
Immunotherapy

3L-20-1

Trial Leaders:
Anthony El-Khoueiry

A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled,Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) withPembrolizumab (MK-3475) in Combination with Transarterial Chemoembolization (TACE) Versus TACE in Participants with Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012)

Treatment:
Chemotherapy: Local
Radiation: Other

3P-18-2

Trial Leaders:
Diana Hanna

Phase 1/2 Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GP-2250 in Combination with Gemcitabine in Subjects with Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma Who Have Progressed on Prior Treatment with FOLFIRINOX Chemotherapy

Treatment:
Chemotherapy: Systemic

3P-19-1

Trial Leaders:
Diana Hanna

A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with Gemcitabine Plus Nab-paclitaxel as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer

Treatment:
Chemotherapy: Systemic
Immunotherapy

3P-19-3

Trial Leaders:
Heinz Josef Lenz

PhI-107:A Phase I study of Anetumab Ravtansine in Combination with either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma

Treatment:
Chemotherapy: Systemic

4B-14-2

Trial Leaders:
Hooman Djaladat

Prevention of parastomal hernia following radical cystectomy and ileal conduit using biologic mesh: Randomized Clinical Trial

Treatment:
Other

4B-15-11

Trial Leaders:
Sarmad Sadeghi

A Phase II Trial of sEphB4-HSA in Combination with Anti PD1 Antibody (Pembrolizumab, MK-3475) for Solid Tumors

Treatment:
Immunotherapy

4B-17-5

Trial Leaders:
David Quinn

PhII-150 A Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination with Atezolizumab Compared to Atezolizumab Alone in Subjects with Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Platinum-Based Treatment is Not an Option

Treatment:
Chemotherapy: Systemic

4B-18-5

Trial Leaders:
David Quinn

PhII-176 A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma with DNA-Repair Defects

Treatment:
Chemotherapy: Systemic

4B-19-6

Trial Leaders:
Siamak Daneshmand

Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF 302)

Treatment:
Immunotherapy

4B-20-1

Trial Leaders:
Siamak Daneshmand

INtravesical Phase 1/1b study of STING Agonist E7766 in NMIBC including subjects Unresponsive to BCG Therapy, INPUT-102

Treatment:
Immunotherapy

4K-16-5

Trial Leaders:
Sarmad Sadeghi

Phase II Randomized Double Blind Trial of PF 04518600, an OX40 Antibody, in Combination with Axitinib versus Axitinib in Immune-Checkpoint Inhibitor Exposed Patients with Metastatic Renal Cell Carcinoma

Treatment:
Immunotherapy

4K-18-2

Trial Leaders:
Haris Zahoor

A Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma

Treatment:
Immunotherapy

4P-16-2

Trial Leaders:
David Quinn

Immune Activation and Cellular Response from Enzalutamide Alone or with Radium223 in Men with Metastatic, Castration-Resistant Prostate Cancer

Treatment:
Other

4P-17-3

Trial Leaders:
Mitchell Gross

TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician’s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency

Treatment:
Hormone
Other

4P-18-2

Trial Leaders:
Monish Aron Monish

SIMCAP (Surgery in Metastatic Carcinoma of Prostate): Phase 2.5 multi-institution randomized prospective clinical trial evaluating the impact of cytoreductive radical prostatectomy combined with best systemic therapy on oncologic and quality of life outcomes in men with newly diagnosed metastatic prostate cancer

Treatment:
Chemotherapy: Systemic
Hormone
Surgery

4P-19-1

Trial Leaders:
Leslie Ballas

Prospective study of stereotactic body radiotherapy (SBRT) following radical prostatectomy

Treatment:
Radiation: External

4P-19-5

Trial Leaders:
David Quinn

A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Progressed on a Next Generation Hormonal Agent (NHA) (MK-3475-921) (KEYNOTE-921)

Treatment:
Chemotherapy: Systemic
Immunotherapy

5C-17-2

Trial Leaders:
Koji Matsuo

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma

Treatment:
Chemotherapy: Systemic
Immunotherapy
Other

5GYN-16-2

Trial Leaders:
Lynda Roman

A Two-Cohort, Open Label, Phase 2 Trial of the IRX 2 Regimen in Women with Squamous Cervical Intraepithelial Neoplasia 3 (CIN 3) or Vulvar Intraepithelial Neoplasia 3 (VIN 3)

Treatment:
Chemotherapy: Systemic

5O-18-1-GOG-3018

Trial Leaders:
Koji Matsuo

A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

Treatment:
Anti-Angiogenesis
Chemotherapy: Systemic

6B-15-1

Trial Leaders:
Thomas Chen

Pilot Trial of NovoTTF -200A (TTFields) in Patients with High Risk Oligodendrogliomas

Treatment:
(No treatments specified)

6B-17-1

Trial Leaders:
James Hu

A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy STELLAR Study

Treatment:
Chemotherapy: Systemic
Other

6G-15-2

Trial Leaders:
James Hu

An Open-Label, Phase 1/2a Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent Grade IV Glioma

Treatment:
Other

7H-17-1

Trial Leaders:
Jorge Nieva

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) for the Treatment of Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Treatment:
Immunotherapy
Vaccine

7H-18-2

Trial Leaders:
Jorge Nieva

Accuracy Study: A Phase 2, Open-Label, Multi-Center Study of AL101 in Patients with Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations

Treatment:
Anti-Angiogenesis

7H-19-1

Trial Leaders:
Bing Xia

PhII-191: Phase II Study of XL184 (Cabozantinib) in Combination with Nivolumab and Ipilimumab (CaboNivoIpi) in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy

Treatment:
Other

7H-19-2

Trial Leaders:
Adam Garsa

PhI-114:Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent HNSCC

Treatment:
Radiation: External

9L-16-15

Trial Leaders:
Casey O'Connell

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination with Ruxolitinib in Subjects with Myelofibrosis

Treatment:
Chemotherapy: Systemic
Other

9L-16-3

Trial Leaders:
Casey O'Connell

A Phase I/II Multicenter Study Combining Guadecitabine, a DNA Methyltransferase Inhibitor, with Atezolizumab, an Immune Checkpoint Inhibitor, in Patients with Intermediate or High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Treatment:
Other

9L-17-10

Trial Leaders:
Casey O'Connell

A Phase 2 Single-Arm, Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax in Combination with Ruxolitinib in Subjects with Myelofibrosis

Treatment:
Chemotherapy: Systemic

9L-17-13

Trial Leaders:
Kevin Kelly

PhI-92: (NCI 10075) A Phase 1B Study of AMG-232 in Combination with Decitabine in Acute Myeloid Leukemia

Treatment:
Chemotherapy: Systemic

9L-17-6

Trial Leaders:
Kevin Kelly

Phase 1b/II Study of Escalating Doses of Pevonedistat (Tak-924, Formerly Mln4924) Administered in Combination with Standard Induction Chemotherapy (Cytarabine and Idarubicin) in Newly Diagnosed High Risk Acute Myelogenous Leukemia (AML)

Treatment:
Chemotherapy: Systemic

9L-18-15

Trial Leaders:
Casey O'Connell

A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera

Treatment:
Chemotherapy: Systemic

9L-18-18

Trial Leaders:
George Yaghmour

A Phase 4, open-label, randomized study of two Inotuzumab Ozogamicin dose levels in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia eligible for hematopoietic stem cell transplantation and who have risk factor(s) for veno-occlusive disease

Treatment:
(No treatments specified)

9L-18-7

Trial Leaders:
George Yaghmour

A Phase 1 Dose Escalation Trial of SKI-G-801 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Treatment:
(No treatments specified)

9L-18-9

Trial Leaders:
George Yaghmour

A Phase 2 Study of Ibrutinib and Blinatumomab in Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia

Treatment:
Chemotherapy: Systemic

9L-19-3

Trial Leaders:
Casey O'Connell

A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy

Treatment:
Other

9L-19-4

Trial Leaders:
George Yaghmour

A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Treatment:
Chemotherapy: Local

9L-20-1

Trial Leaders:
George Yaghmour

NCI 10273 / PhI-103: A Phase I Study of M3814 in Combination with MEC in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Treatment:
Chemotherapy: Systemic
Vaccine

9L-20-2

Trial Leaders:
Casey O'Connell

Phase 3 Study (PACIFICA): A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL)

Treatment:
(No treatments specified)

CTSU- A021502

Trial Leaders:
Heinz Josef Lenz

Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair

Treatment:
Chemotherapy: Systemic

CTSU-A011502

Trial Leaders:
Irene Kang

A randomized phase III double blinded placebo-controlled trial of aspirin as adjuvant therapy for HER2 negative breast cancer: the ABC trial

Treatment:
(No treatments specified)

CTSU-A021703

Trial Leaders:
Heinz Josef Lenz

Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)

Treatment:
Chemotherapy: Systemic

CTSU-A031102

Trial Leaders:
James Hu

A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy using Mobilizing Paclitaxel plus Ifosfamide followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors

Treatment:
Chemotherapy: Systemic

CTSU-A031501

Trial Leaders:
David Quinn

Phase III randomized “Adjuvant study of MK-3475 (pembrolizumab) in muscle invasive and locally advanced urothelial carcinoma” (AMBASSADOR) versus observation

Treatment:
Immunotherapy

CTSU-A031702

Trial Leaders:
Anishka D'Souza

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

Treatment:
Chemotherapy: Systemic
Immunotherapy

CTSU-A071801

Trial Leaders:
Eric Chang

Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease

Treatment:
Radiation: External

CTSU-A081105

Trial Leaders:
Jorge Nieva

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Treatment:
Chemotherapy: Systemic

CTSU-A091802

Trial Leaders:
Gino In

Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)

Treatment:
Chemotherapy: Systemic

CTSU-A221505

Trial Leaders:
Naomi Schechter

Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction

Treatment:
Radiation: External

CTSU-AGCT1531

Trial Leaders:
Anishka D'Souza

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

Treatment:
Chemotherapy: Systemic

CTSU-AGCT1532

Trial Leaders:
Anishka D'Souza

A randomized phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumors

Treatment:
Chemotherapy: Systemic

CTSU-E4512

Trial Leaders:
Jorge Nieva

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Treatment:
Chemotherapy: Systemic

CTSU-EA2165

Trial Leaders:
Syma Iqbal

A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

Treatment:
Chemotherapy: Systemic
Immunotherapy

CTSU-EA6174

Trial Leaders:
Gino In

Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma

Treatment:
Immunotherapy

CTSU-EA8134

Trial Leaders:
Anne Schuckman

International Penile Advanced Cancer Trial

Treatment:
Chemotherapy: Systemic
Surgery

CTSU-EAY131

Trial Leaders:
Heinz Josef Lenz

Molecular Analysis for Therapy Choice (MATCH)

Treatment:
(No treatments specified)

ctsu/NSABP-51/RTOG1304

Trial Leaders:
Naomi Schechter

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

Treatment:
Radiation: External

NC-HEM-19-7

Trial Leaders:
Howard Liebman

Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Study

Treatment:
(No treatments specified)

NC-HEM-20-3

Trial Leaders:
Caroline Piatek

A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome

Treatment:
Immunotherapy

NRG-BN003

Trial Leaders:
Eric Chang

Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma

Treatment:
Other

NRG-GU005

Trial Leaders:
Leslie Ballas

Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for localized intermediate risk prostate cancer

Treatment:
Radiation: External

NRG-GU008

Trial Leaders:
Leslie Ballas

Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging Into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy

Treatment:
Other

NRG-HN005

Trial Leaders:
Adam Garsa

A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer

Treatment:
(No treatments specified)

NRG-LU005

Trial Leaders:
Jason Ye

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab (MPDL3280A)

Treatment:
Chemotherapy: Systemic
Radiation: External

RTOG-0724

Trial Leaders:
Koji Matsuo

Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy

Treatment:
Chemotherapy: Systemic

SWOG-S0820

Trial Leaders:
Syma Iqbal

A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer or Rectal Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES).

Treatment:
Other

SWOG-S1418-BR006

Trial Leaders:
Janice Lu

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy.

Treatment:
Chemotherapy: Systemic

SWOG-S1501

Trial Leaders:
Irene Kang

Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III

Treatment:
Other

SWOG-S1512

Trial Leaders:
Gino In

A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unsectable Desmoplastic Melanoma (DM)

Treatment:
Other

SWOG-S1602

Trial Leaders:
Siamak Daneshmand

A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle Invasive Bladder Cancer

Treatment:
Biological Response Modifier
Chemotherapy: Local

SWOG-S1609

Trial Leaders:
Heinz Josef Lenz

DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors

Treatment:
Immunotherapy

SWOG-S1613

Trial Leaders:
Heinz Josef Lenz

A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) with HER-2 Amplification

Treatment:
Chemotherapy: Systemic
Immunotherapy

SWOG-S1706

Trial Leaders:
Jason Ye

A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer

Treatment:
Chemotherapy: Systemic
Radiation: External

SWOG-S1801

Trial Leaders:
Gino In

A phase II randomized study of adjuvant versus neoadjuvant MK-3475 (pembrolizumab) for clinically detectable stage III-IV high risk melanoma

Treatment:
Other

SWOG-S1802

Trial Leaders:
Siamak Daneshmand

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

Treatment:
Chemotherapy: Systemic
Hormone

SWOG-S1806

Trial Leaders:
Leslie Ballas

Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer

Treatment:
Chemotherapy: Systemic
Immunotherapy

SWOG-S1815

Trial Leaders:
Anthony El-Khoueiry

A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

Treatment:
Chemotherapy: Systemic

SWOG-S1827

Trial Leaders:
Jason Ye

MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)

Treatment:
Radiation: External

Phase I trials for all solid tumors:


0C-14-9

Trial Leaders:
Anthony El-Khoueiry

A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of ceralasertib in combination with Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients with Advanced Solid Malignancies

Treatment:
Chemotherapy: Systemic

0C-16-6

Trial Leaders:
Anthony El-Khoueiry

PhI-87 Phase I Clinical Trial of M6220 (VX-970) in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-16-8

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects with Advanced Refractory Cancers

Treatment:
Chemotherapy: Local

0C-17-1

Trial Leaders:
Anthony El-Khoueiry

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 skip mutations and c-Met Dysregulation Advance Solid Tumors

Treatment:
Other

0C-17-11

Trial Leaders:
Diana Hanna

Phase 1 trial of ZW25 in patients with locally advanced (unresectable) and/or metastatic HER2-expressing cancers

Treatment:
Other

0C-17-17

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2 First-in-human Study of BMS-986258 Alone and in Combination with Nivolumab in Advanced Malignant Tumors

Treatment:
Immunotherapy

0C-17-2

Trial Leaders:
David Quinn

A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects with Advanced Cancers

Treatment:
Biological Response Modifier
Chemotherapy: Systemic

0C-18-12

Trial Leaders:
Anthony El-Khoueiry

A phase I, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK3368715 in participants with solid tumors and DLBCL

Treatment:
Chemotherapy: Systemic

0C-18-16

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2 Open-label, Multicenter Study To Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884)in Subjects With Advanced or Refractory Cancer and in Subjects who have Progressed During Treatment with a PD-1/PD-L1 Inhibitor as their Most Recent Therapy

Treatment:
Immunotherapy

0C-18-2

Trial Leaders:
Anthony El-Khoueiry

A Phase I Study of FID-007 in Patients with Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-18-20

Trial Leaders:
Jacob Thomas

A Phase 1 Dose-escalation Study of FF-10832 Monotherapy or in Combination with Nab-paclitaxel for the Treatment of Advanced Solid Tumors

Treatment:
(No treatments specified)

0C-18-21

Trial Leaders:
Diana Hanna

A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.

Treatment:
Chemotherapy: Systemic
Immunotherapy

0C-18-23

Trial Leaders:
Anthony El-Khoueiry

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms

Treatment:
Immunomodulator

0C-18-24

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176

Treatment:
Immunotherapy

0C-18-5

Trial Leaders:
Heinz Josef Lenz

An open-label, Phase I trial to determine the maximum-tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 905677 administered intravenously in patients with advanced solid tumours

Treatment:
Chemotherapy: Systemic

0C-18-7

Trial Leaders:
Anthony El-Khoueiry

A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas

Treatment:
Chemotherapy: Systemic

0C-19-10

Trial Leaders:
Anthony El-Khoueiry

A Phase 1, Open-label, Dose-escalation and Expansion Study of MEDI1191 Administered Intratumorally as Monotherapy and in Combination with Durvalumab in Subjects with Advanced Solid Tumors

Treatment:
Immunotherapy

0C-19-12

Trial Leaders:
Heinz Josef Lenz

A Phase 1a/b Dose-Finding Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

Treatment:
Chemotherapy: Systemic
Other

0C-19-15

Trial Leaders:
Anthony El-Khoueiry

A Phase 1 Study of AGEN1223, a Bispecific Fc-Engineered Anti-GITR-OX40 Antibody in Subjects with Advanced Solid Tumors

Treatment:
Immunotherapy

0C-19-2

Trial Leaders:
Jacob Thomas

A Phase 1, open label, first-in-human study of TR1801-ADC, an antibody drug conjugate (ADC), in patients with select solid tumors expressing c-Met

Treatment:
Other

0C-19-20

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AFM24 in Patients with Advanced Solid Cancers

Treatment:
Immunotherapy

0C-19-21

Trial Leaders:
Diana Hanna

A Phase I Study of GNX102 in patients with Advanced Solid Tumors

Treatment:
Immunotherapy

0C-19-22

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients with Advanced Cancers Associated with Mesothelin Expression Who Have Failed Standard Available Therapy

Treatment:
Biological Response Modifier

0C-19-3

Trial Leaders:
Jacob Thomas

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

Treatment:
Immunotherapy

0C-19-4

Trial Leaders:
Anthony El-Khoueiry

Phase 1 Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety of Lorlatinib in Advanced Cancer Patients

Treatment:
Immunotherapy

0C-19-6

Trial Leaders:
Anthony El-Khoueiry

A Phase I Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor (CDAi) with Oral Decitabine in Subjects with Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-19-7

Trial Leaders:
Anthony El-Khoueiry

A Phase 1 Study of AGEN1181, an Fc-Engineered Anti–CTLA-4 Monoclonal Antibody as Monotherapy and in Combination with AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancer

Treatment:
Immunotherapy

0C-19-8

Trial Leaders:
Heinz Josef Lenz

A multicentre, open-label, non randomised first in human study of NG-641, an oncolytic transgene expressing adenoviral vector, in patients with metastatic or advanced epithelial tumours (STAR)

Treatment:
Immunomodulator

0C-20-1

Trial Leaders:
Anthony El-Khoueiry

A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability,Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications

Treatment:
Immunotherapy

0C-20-2

Trial Leaders:
Anthony El-Khoueiry

Phase 1/1b Study to Evaluate the Safety and Activity of TTX-030 (Anti-CD39) in Combination with Budigalimab and/or Chemotherapy in Subjects with Advanced Solid Tumors

Treatment:
(No treatments specified)

0C-20-7

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/1b, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1454 alone and in Combination with Ipilimumab and Nivolumab

Treatment:
Other

0C-20-8

Trial Leaders:
Heinz Josef Lenz

First-In-Human Dose-Escalation Study of STP1002 in Patients with Advanced-Stage Solid Tumors

Treatment:
Other

0C-20-9

Trial Leaders:
Anthony El-Khoueiry

A Phase 1 Study of AGEN2373, an Anti–CD137 Monoclonal Antibody, in Subjects with Advanced Cancer

Treatment:
Other

TEST002

Trial Leaders:
Francisco Acosta

Test Protocol 002 Long Protocol Title112

Treatment:
Autologous Bone Marrow Transplant
Biological Response Modifier
Chemotherapy: Local
Genetic




Trials which are NOT treatments of disease. Specimens or information may be collected:


0C-19-9

Trial Leaders:
Jacob Thomas

A Phase II, Open Label, Multi-Dose Study of 89Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients with Advanced or Metastatic Melanoma, Non Small Cell Lung Cancer, Renal Cell Carcinoma or Squamous Cell Carcinoma of the Head and Neck Selected to Receive Standard-Of-Care Immunotherapy as Single Agent or in Combination


0S-04-7

Trial Leaders:
Michael Press

USC Tumor and Tissue Bank.


0S-11-5

Trial Leaders:
Amir Goldkorn

Circulating Tumor Cell Collection from Cancer Patients.


0S-15-12

Trial Leaders:
John Carpten

Norris ORIEN Total Cancer Care Protocol: A Lifetime Partnership with Patients.


0S-15-16

Trial Leaders:
Casey O'Connell

Protocol for Immunology Specimen Collection from Cancer Patients, Patients with Hematologic Diagnoses, and Healthy Normal Controls


0S-15-7

Trial Leaders:
Semara Thomas

Long Term Effects of Tyrosine Kinase Inhibitors on Ovarian Reserve and Fertility-A pilot study,A Pilot Study


0S-16-1

Trial Leaders:
Shannon Mumenthaler

Characterization of Mechanical Tissue Properties in Pancreas, Liver and Colon


0S-16-9

Trial Leaders:
Ebrahim Zandi

The Role of Microbiome in Cancer Therapy


0S-18-5

Trial Leaders:
Darcy Spicer

Improving Patient Access to Cancer Clinical Trials ( iMPACT Study)


0S-18-8

Trial Leaders:
Jorge Nieva

Precision Performance Status Assessment in Early Phase Clinical Trials


0S-19-4

Trial Leaders:
Jacob Thomas

A Tissue Collection Study in Patients who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells


0S-99-10

Trial Leaders:
Heinz Josef Lenz

Blood Collection in Patients with GI Cancer and Patients Undergoing Endoscopy


16M-18-2

Trial Leaders:
Leslie Ballas

Phase II Multi-Institutional Study of Low-Dose (2Gy x 2) Palliative Radiotherapy in the Treatment of Symptomatic Bone metastases from Multiple Myeloma


1B-11-1

Trial Leaders:
Julie Lang

Breast Cancer Blood Biorepository.


1B-12-6

Trial Leaders:
Jaques Van Dam

Light-Scattering Spectroscopy for the Detection of Stage II-III Breast Cancer: A Pilot Study.


1B-13-2

Trial Leaders:
Julie Lang

Core Biopsies of Breast Tumor Tissue Repository.


1B-16-3

Trial Leaders:
Mary W. Yamashita

Emerging Tools in the Detection of Breast Cancer: Comparison of Contrast Enhanced Spectral Mammography with Digital Breast Tomosynthesis to Conventional Imaging Techniques Including Contrast Enhanced Magnetic Resonance Imaging and 2D Mammography with or without Targeted Ultrasound


1B-17-1

Trial Leaders:
Julie Lang

Combined Breast MRI/Biomarker Strategies to Identify Aggressive Biology


2L-17-1

Trial Leaders:
Pamela Ward

Liquid Biopsy Research Project


2N-19-3

Trial Leaders:
Jorge Nieva

Establishing a Diagnosis of Lung Cancer Through a Fluid Biopsy


3C-18-2

Trial Leaders:
Heinz Josef Lenz

Detection of Microsatellite Instability in circulating tumor DNA of patients with stage IV Colorectal Carcinoma


3C-19-4

Trial Leaders:
Kimberly  Miller

Colorectal Cancer in Adolescents and Young Adults: A Pilot Study of Medical and Psychosocial Issues


3C-20-1

Trial Leaders:
Heinz Josef Lenz

COLOMATE: COlorectal Cancer Liquid BiOpsy Screening Protocol for Molecularly Assigned ThErapy


3G-07-3

Trial Leaders:
Heinz Josef Lenz

Establishing Continuous Cell Lines and Xenografts from Adult Malignant Solid Tumors and Inflammatory Bowel Disease for Biological and Pre-Clinical Therapeutic Studies.


3L-17-4

Trial Leaders:
Syma Iqbal

A 5-year Longitudinal Observational Study of the Natural History and Management of Patients with Hepatocellular Carcinoma


4B-15-2

Trial Leaders:
Jacek Pinski

MDSC Clinical Assay for Cancer Detection And Monitoring in Bladder Carcinoma


4B-19-1

Trial Leaders:
Sumeet Bhanvadia

Use of a multiplexed molecular biomarker test Cxbladder, in Real World decision making to provide Clinical Utility Using a Randomized Design


4B-19-4

Trial Leaders:
Siamak Daneshmand

The Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) for Bladder Cancer Study


4K-03-2

Trial Leaders:
Eila Skinner

Kidney Cancer Data and Specimen Collection Project.


4K-14-4

Trial Leaders:
Jacek Pinski

MDSC Clinical Assay for Cancer Detection and Monitoring in Renal Cell Carcinoma


4P-01-2

Trial Leaders:
Eila Skinner

Prostate Cancer Prostatectomy Data and Specimen Collection Project.


4P-11-4

Trial Leaders:
Mitchell Gross

Multi-Dimensional Assessment of Circulating Tumor Cells in Patients Treated For Metastatic Prostate Cancer.


4P-12-3

Trial Leaders:
Alan Epstein

MDSC Clinical Assay for Cancer Detection and Monitoring in Prostate Cancer.


4P-16-3

Trial Leaders:
Hossein Jadvar

Pilot Feasibility Study of 18f-FMAU PET for Diagnosing and Characterizing Prostate Cancer


4P-16-7

Trial Leaders:
Inderbir Gill

Diagnosing Clinically Significant Prostate Cancer in African American and White Men Phase II, Randomized Clinical Trial, Multi-Center, MR-guided vs. 12-core Systematic Random Biopsy, Localized Prostate Cancer


4P-17-4

Trial Leaders:
Siamak Daneshmand

Prospective Validation of Prostate Biomarkers for Repeat Biopsy: The PRIORITY Study


4P-17-8

Trial Leaders:
Jonathan Katz

Method Development and Assessment of Pre-Analytical Variables for Metabolomic Analysis of Peripheral Blood Mononucleocytes from Whole Blood Draws


4P-19-4

Trial Leaders:
Mark Shiroishi

A Pilot Study of 7 Tesla MRI Neuroimaging Biomarkers of Prostate Cancer-Related Cognitive Impairment


5GYN-10-3

Trial Leaders:
Lynda Roman

Banking Tissues from Normal and Disease-Related Gynecologic Surgeries.


5O-19-1

Trial Leaders:
Marcia Ciccone

Clinical Validation of the Inter Venn Ovarian Cancer Liquid Biopsy


6CNS-07-1

Trial Leaders:
Thomas Chen

Establishment of USC CNS and Spine Tumor Bank.


7H-16-2

Trial Leaders:
Mark Shiroishi

A Pilot Study of Whole-Neck CT Perfusion with the Toshiba Aquilion One Vision-320 Detector Row CT Scanner For Use In Head & Neck Tumor Patients


9L-10-3

Trial Leaders:
Preet Chaudhary

Comprehensive Hematology Tissue Repository (BANK).


9L-16-10

Trial Leaders:
Houda Alachkar

Characterization of T-cell Repertoire in Patients with AML undergoing HSCT through Next-Generation Sequencing of TCRA and TCRB Genes


CTSU-A151216

Trial Leaders:
Jorge Nieva

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)


CTSU-EA1151

Trial Leaders:
Linda Hovanessian

Comparison of Tomosynthesis to Digital Mammography in Breast Cancer Screening


CTSU-EAF151

Trial Leaders:
Mark Shiroishi

Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma


NC-HEM-05-4

Trial Leaders:
Casey O'Connell

Hematology Database


NC-HEM-19-3

Trial Leaders:
Caroline Piatek

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study to Evaluate the Efficacy and Safety of Oral SKI-O-703, SYK Inhibitor, in Patients with Persistent and Chronic Immune Thrombocytopenia (ITP)


NC-HEM-19-4

Trial Leaders:
Caroline Piatek

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia


NC-HEM-20-2

Trial Leaders:
Caroline Piatek

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia


SWOG-S1823

Trial Leaders:
Siamak Daneshmand

A Prospective Observational Cohort Study to Assess miRNA 371 For Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors